Supplementary tables Table 1: All-cause mortality and serious adverse events by age and sex. †Mortality based on patients undergoing surgery 2012-2017 only.

| | | | | 30-davs | 90-days | | |
|--------------|---------------|-------------|-----------|---------------------------|-----------|---|--|
| Age | | Number at | Number | Incidence | Number | Incidence | |
| (vears) | Sex | risk | of events | % (95% CI) | of events | % (95% CI) | |
| Mortalityt | UCA | non | or events | , (55, 6 Cl) | or crents | , (35 / 5 C / 7 | |
| 50-64 | Male | 1865 | 2 | 0 11% (0 03 to 0 43) | 4 | 0 21% (0 08 to 0 57) | |
| 65-74 | | 2898 | 3 | 0.10% (0.03 to 0.32) | 9 | 0.31% (0.16 to 0.60) | |
| 75-84 | | 2000 | 10 | 0.46% (0.05 to 0.32) | 17 | 0.78% (0.49 to 1.26) | |
| 85+ | | 305 | 12 | 3 93% (2 23 to 6 93) | 17 | 5 57% (3 16 to 8 97) | |
| 50-64 | Fomale | 2311 | 1 | 0.04% (0.01 to 0.31) | 3 | $0.13\% (0.04 \pm 0.040)$ | |
| 65-74 | remaie | 6603 | 7 | 0.04% (0.01 to 0.01) | 12 | 0.13% (0.04 to 0.40) | |
| 75-84 | | 7/10 | 10 | 0.11% (0.05 to 0.22) | 25 | $0.10\% (0.10\ 0.0.52)$ | |
| 75-84 95- | | 1410 | 10 | 0.13% (0.07 to 0.23) | 25 | 2.15% (0.23 to 0.30) | |
| Mussardia | Linforction | 1444 | 12 | 0.90% (0.32 (0 1.33) | 51 | 2.13%(1.51 (0 3.03) | |
| FO 64 | Male | 1750 | Δ | $0.08\% (0.02 \pm 0.02)$ | 0 | $0.10\% (0.10 \pm 0.26)$ | |
| 50-64 | IVIAIE | 4756 | 4 | 0.08% (0.03 to 0.22) | 9 | 0.19% (0.10(0.0.30)) | |
| 75.94 | | 4270 | 9 | 0.14% (0.07 (0.0.27)) | 10 | 0.25% (0.10(0.041)) | |
| 75-64 | | 4270 | 12 | 0.28% (0.10 (0 0.49) | 24 | 0.50% (0.58 (0.04) | |
| 85+ | F 1 - | 637 | 7 | 1.10% (0.52 to 2.31) | 9 | 1.41% (0.74 to 2.72) | |
| 50-64 | Female | 15250 | 2 | 0.03% (0.01 (0.0.12) | 3 | 0.05% (0.01 (0.0.14) | |
| 65-74 | | 15258 | 24 | 0.16% (0.11 to 0.23) | 26 | 0.17% (0.12 to 0.25) | |
| 75-84 | | 16/16 | 41 | 0.25% (0.18 to 0.33) | 52 | 0.31% (0.24 to 0.41) | |
| 85+ | | 3446 | 22 | 0.64% (0.42 to 0.97) | 22 | 0.64% (0.42 to 0.97) | |
| Pulmonary | embolism | 4750 | | 0.430/ (0.001 - 0.00) | _ | 0 100/ /0 10 1 0 00 | |
| 50-64 | Male | 4758 | 6 | 0.13% (0.06 to 0.28) | 9 | 0.19% (0.10 to 0.36) | |
| 65-74 | | 6309 | 6 | 0.10% (0.04 to 0.21) | 10 | 0.16% (0.09 to 0.29) | |
| 75-84 | | 4270 | 12 | 0.28% (0.16 to 0.49) | 17 | 0.40% (0.25 to 0.64) | |
| 85+ | | 637 | 4 | 0.63% (0.24 to 1.67) | 4 | 0.63% (0.24 to 1.67) | |
| 50-64 | Female | 6660 | 10 | 0.15% (0.08 to 0.28) | 14 | 0.21% (0.12 to 0.35) | |
| 65-74 | | 15258 | 24 | 0.16% (0.11 to 0.23) | 33 | 0.22% (0.15 to 0.30) | |
| 75-84 | | 16716 | 36 | 0.22% (0.16 to 0.30) | 55 | 0.33% (0.25 to 0.43) | |
| 85+ | | 3446 | 8 | 0.23% (0.12 to 0.46) | 14 | 0.41% (0.24 to 0.69) | |
| Lower resp | piratory trac | t infection | | | | | |
| 50-64 | Male | 4758 | 35 | 0.74% (0.53 to 1.02) | 43 | 0.90% (0.67 to 1.22) | |
| 65-74 | | 6309 | 63 | 1.00% (0.78 to 1.28) | 79 | 1.25% (1.00 to 1.56) | |
| 75-84 | | 4270 | 107 | 2.51% (2.07 to 3.03) | 140 | 3.28% (2.78 to 3.87) | |
| 85+ | | 637 | 66 | 10.36% (8.14 to 13.19) | 81 | 12.72% (10.23 to 15.81) | |
| 50-64 | Female | 6660 | 57 | 0.86% (0.66 to 1.11) | 76 | 1.14% (0.91 to 1.43) | |
| 65-74 | | 15258 | 147 | 0.96% (0.82 to 1.13) | 194 | 1.27% (1.10 to 1.46) | |
| 75-84 | | 16716 | 277 | 1.66% (1.47 to 1.86) | 356 | 2.13% (1.92 to 2.36) | |
| 85+ | | 3446 | 118 | 3.42% (2.86 to 4.10) | 141 | 4.09% (3.47 to 4.83) | |
| Acute kidn | ey injury | | | · · · · · · | | | |
| 50-64 | Male | 4758 | 23 | 0.48% (0.32 to 0.73) | 27 | 0.57% (0.39 to 0.83) | |
| 65-74 | | 6309 | 43 | 0.68% (0.51 to 0.92) | 46 | 0.73% (0.55 to 0.97) | |
| 75-84 | | 4270 | 81 | 1.90% (1.53 to 2.36) | 87 | 2.04% (1.65 to 2.51) | |
| 85+ | | 637 | 23 | 3.61% (2.40 to 5.43) | 30 | 4.71% (3.29 to 6.74) | |
| 50-64 | Female | 6660 | 13 | 0.20% (0.11 to 0.34) | 20 | 0.30% (0.19 to 0.47) | |
| 65-74 | | 15258 | 83 | 0.54% (0.44 to 0.67) | 101 | 0.66% (0.54 to 0.80) | |
| 75-84 | | 16716 | 149 | 0.89% (0.76 to 1.05) | 183 | 1.09% (0.95 to 1.27) | |
| 85+ | | 3446 | 60 | 1.74% (1.35 to 2.24) | 71 | 2.06% (1.63 to 2.60) | |
| Urinary tra | ct infection | 0110 | | | | 2.0073 (2.00 10 2.00) | |
| 50-64 | Male | 4758 | 12 | 0.25% (0.14 to 0.44) | 15 | 0.32% (0.19 to 0.52) | |
| 65-74 | mare | 6300 | 32 | $0.51\% (0.36 \pm 0.072)$ | 50 | 0.79% (0.60 to 1.05) | |
| 75 94 | | 4270 | 10 | $1.12\% (0.85 \pm 0.140)$ | 71 | $1.66\% (1.22 \pm 0.210)$ | |
| 851 | | 4270 | 40 | $3.61\% (2.40 \pm 0.51)$ | 21 | 1.00% (1.52 t0 2.10) 4.87% (2.42 to 6.02) | |
| 50.64 | Fomalo | 6660 | 23 | $0.41\% (0.28 \pm 0.050)$ | 20 | 4.87%(3.42(00.52)) | |
| 65 74 | remale | 15259 | 102 | 0.4170 (0.20 (0.039) | 145 | 0.57% (0.42 (0.0.78)) 0.05% (0.91 to 1.12) | |
| 75.94 | | 15258 | 102 | $1.25\% (1.10 \pm 0.151)$ | 200 | 0.55% (0.61 (0 1.12) 1 85% (1 65 to 2.07) | |
| 75-64 95. | | 20/10 | 220 | 1.55% (1.19 (0 1.54) | 150 | 1.05% (1.05 10 2.07) 1.25% (2.71 + 0.5.11) | |
| 00+ | | 3440 | 123 | 5.57% (2.99 to 4.26) | 150 | 4.55% (3.71 (0 5.11) | |
| Cerebrova: | Male | 4750 | Δ | $0.08\% (0.02 \pm 0.02)$ | C C | 0.12% (0.06 + 0.20) | |
| 50-64 | wate | 4758 | 4 | 0.08% (0.03 to 0.22) | 0 | 0.13% (0.06 to 0.28) | |
| 75-74 | | 6309 | 9 | 0.14% (0.07 to 0.27) | 14 | 0.22% (0.13 (0.037)) | |
| /5-84 | | 4270 | 12 | 0.28% (0.16 to 0.49) | 23 | 0.54% (0.36 to 0.81) | |
| 85+ | Factor 1 | 63/ | 3 | 0.47% (0.15 to 1.46) | 4 | 0.63% (0.24 to 1.67) | |
| 50-64 | Female | 6660 | 0 | 0.00% (0.00 to 0.00) | 0 | 0.00% (0.00 to 0.00) | |
| 65-74 | | 15258 | 8 | 0.05% (0.03 to 0.10) | 23 | 0.15% (0.10 to 0.23) | |
| 75-84 | | 16716 | 30 | 0.18% (0.13 to 0.26) | 47 | 0.28% (0.21 to 0.37) | |
| 85+ | | 3446 | 15 | (0.44%)(0.26 to 0.72) | 20 | 0.58% (0.37 to 0.90) | |

| Age (years) | Sex | Lifetime risk of implant revision | Lifetime risk of any further shoulder surgery |
|----------------|--------|-----------------------------------|---|
| 50-54 | Male | 19.34% (18.93 to 19.75) | 29.75% (29.20 to 30.30) |
| 55-59 | | 23.61% (23.20 to 24.02) | 31.86% (31.36 to 32.37) |
| 60-64 | | 15.86% (15.57 to 16.14) | 24.22% (23.82 to 24.62) |
| 65-69 | | 12.94% (12.75 to 13.13) | 20.36% (20.09 to 20.64) |
| 70-74 | | 10.55% (10.38 to 10.73) | 16.94% (16.64 to 17.24) |
| 75-79 | | 8.03% (7.89 to 8.17) | 13.14% (12.86 to 13.43) |
| 80-84 | | 7.06% (6.88 to 7.24) | 9.08% (8.83 to 9.32) |
| 85+ | | 3.81% (3.65 to 3.97) | 4.37% (4.20 to 4.55) |
| 50-54 | Female | 19.79% (19.41 to 20.18) | 28.01% (27.52 to 28.49) |
| 55-59 | | 19.02% (18.72 to 19.31) | 27.87% (27.47 to 28.27) |
| 60-64 | | 15.20% (15.00 to 15.41) | 22.61% (22.30 to 22.91) |
| 65-69 | | 12.42% (12.25 to 12.59) | 19.41% (19.16 to 19.67) |
| 70-74 | | 9.28% (9.18 to 9.37) | 14.08% (13.89 to 14.27) |
| 75-79 | | 6.42% (6.35 to 6.49) | 9.88% (9.75 to 10.01) |
| 80-84 | | 4.25% (4.18 to 4.31) | 7.63% (7.44 to 7.83) |
| 85+ | | 2.68% (2.62 to 2.75) | 3.70% (3.59 to 3.80) |

Table 2: Estimates of lifetime risk of implant revision or any further shoulder operation, stratified by age and sex

Supplementary tables

 Table 3: Estimated revision risk at 3, 5, 10 and 15 years stratified by age and sex. Risk calculated as 1 minus Kaplan Meier survival function.

 Presented in table as total number of cases performed, estimate, 95% confidence intervals and number remaining at risk (n)

| Male | | | | | | |
|----------------|----------------|--------------------------------|----------------------------------|----------------------------------|----------------------------------|--|
| Age (years) | Total cases | 3 years | 5 years | 10 years | 15 years | |
| 50-54 | 1013 | 8.91% (7.23 to 10.97) n=695 | 11.57% (9.58 to 13.95) n=529 | 16.37% (13.68 to 19.53) n=229 | 20.58% (16.64 to 25.29) n=67 | |
| 55-59 | 1491 | 7.99% (6.63 to 9.61) n=985 | 12.78% (10.96 to 14.87) n=727 | 20.13% (17.53 to 23.07) n=321 | 23.86% (20.39 to 27.82) n=80 | |
| 60-64 | 2254 | 7.6% (6.5 to 8.87) n=1525 | 10.43% (9.09 to 11.95) n=1141 | 13.66% (11.94 to 15.61) n=403 | 16.67% (13.96 to 19.83) n=89 | |
| 65-69 | 3092 | 6.62% (5.73 to 7.64) n=1952 | 8.97% (7.88 to 10.21) n=1394 | 12.82% (11.28 to 14.55) n=462 | 13.79% (11.96 to 15.87) n=100 | |
| 70-74 | 3217 | 6.34% (5.48 to 7.32) n=1934 | 8.48% (7.43 to 9.68) n=1318 | 10.73% (9.36 to 12.28) n=379 | 11.5% (9.80 to 13.47) n=56 | |
| 75-79 | 2786 | 6.46% (5.53 to 7.55) n=1560 | 7.68% (6.6 to 8.92) n=1015 | 9.06% (7.61 to 10.78) n=203 | 9.06% (7.61 to 10.78) n=28 | |
| 80-84 | 1484 | 5.4% (4.28 to 6.79) n=765 | 7.09% (5.66 to 8.85) n=437 | 8.37% (6.58 to 10.63) n=69 | 8.37% (6.58 to 10.63) n=5 | |
| 85+ | 637 | 4.36% (2.93 to 6.47) n=271 | 4.36% (2.93 to 6.47) n=153 | 4.36% (2.93 to 6.47) n=11 | 4.36% (2.93 to 6.47) n=2 | |

Female

| Age (years) | Total cases | 3 years | 5 years | 10 years | 15 years |
|----------------|----------------|--------------------------------|----------------------------------|----------------------------------|----------------------------------|
| 50-54 | 1076 | 7.78% (6.23 to 9.7) n=759 | 11.3% (9.36 to 13.6) n=596 | 16.28% (13.76 to 19.2) n=311 | 19.89% (16.62 to 23.72) n=116 |
| 55-59 | 1942 | 7.71% (6.54 to 9.07) n=1395 | 10.85% (9.41 to 12.48) n=1072 | 16.3% (14.33 to 18.51) n=494 | 19.11% (16.57 to 21.98) n=137 |
| 60-64 | 3642 | 5.99% (5.22 to 6.87) n=2615 | 9.14% (8.15 to 10.24) n=2010 | 13.05% (11.71 to 14.54) n=802 | 15.72% (13.84 to 17.83) n=227 |
| 65-69 | 6306 | 5.39% (4.81 to 6.03) n=4206 | 7.16% (6.47 to 7.92) n=3056 | 10.55% (9.58 to 11.62) n=1176 | 12.67% (11.22 to 14.29) n=260 |
| 70-74 | 8952 | 5.18% (4.71 to 5.71) n=5768 | 6.9% (6.32 to 7.53) n=4162 | 9.12% (8.35 to 9.95) n=1326 | 9.96% (9.00 to 11.01) n=242 |
| 75-79 | 9902 | 4.2% (3.79 to 4.65) n=6259 | 5.51% (5.01 to 6.05) n=4344 | 7.00% (6.33 to 7.72) n=1219 | 7.13% (6.43 to 7.91) n=189 |
| 80-84 | 6814 | 3.24% (2.81 to 3.73) n=4128 | 4.02% (3.52 to 4.59) n=2734 | 4.94% (4.28 to 5.69) n=582 | 4.94% (4.28 to 5.69) n=55 |
| 85+ | 3446 | 2.6% (2.08 to 3.25) n=1966 | 2.89% (2.32 to 3.59) n=1170 | 3.28% (2.59 to 4.16) n=164 | 3.28% (2.59 to 4.16) n=11 |



Supplementary figure 1a: Predicted probability of any serious adverse event within 30 days

Logistic regression based on 58054 cases, 2045 events. Model validation: c-statistic 0.72, Brier score 0.03



Supplementary figure 1b: Predicted probability of any serious adverse event within 90 days

Logistic regression based on 58054 cases, 2677 events. Model validation: c-statistic 0.72, Brier score 0.04

Supplementary methodology notes:

OPCS-4 codes are regularly updated with new codes to reflect evolving medical technology. The standard version used for this study was OPCS-4.7 (mandated for HES use since April 2014). The NHS Technology Reference data Update Distribution provides reference datasets to cross reference these codes to older versions of the OPCS-4. These were applied to the dataset to ensure full capture of relevant cases since 1998. Specifically, in OPCS-4.2, shoulder replacements were identified with the addition of specific anatomy codes. Subsequent to that, standalone shoulder replacement codes are used.

There are 20 diagnosis fields ("DIAG_") in HES which use the ICD-10 coding system. ICD-10 uses a tree structure for codes with up to 5 digits available in HES. Therefore, diagnoses can be identified with fewer digits if the intention is to include all of the subsequent branches. Primary diagnosis codes were based on the information recorded in the FIRST diagnosis field only. Past medical history was taken into account to identify previous conditions which were highly likely to contribute to the indication for surgery. The following hierachy was used to apply these in generating the final main indication: 1. Bone tumour, 2. Acute trauma, 3. Previous trauma, 4. Avascular necrosis, 5. Inflammatory, 6. Osteoarthritis and cuff tear arthropathy, 7. Other

The Charlson Comorbidity Index was calculated using the Stata function -charlson (Vicki Stagg, 2006. "CHARLSON: Stata module to calculate Charlson index of comorbidity," Statistical Software Components S456719, Boston College Department of Economics, revised 13 Sep 2017).

The following pages of tables describe the relevant OPCS-4 and ICD-10 codes used in this study.

Primary procedure codes

| Main code | Anatomy code |
|-----------|--------------|
| W431 | Z685 |
| W431 | Z691 |
| W431 | Z814 |
| W431 | Z814 |
| W431 | Z814 |
| W441 | Z814 |
| W441 | Z814 |
| W451 | Z814 |
| W451 | Z814 |
| W491 | n/a |
| W494 | n/a |
| W501 | n/a |
| W504 | n/a |
| W511 | n/a |
| W515 | n/a |
| W581 | Z691 |
| W581 | Z813 |
| W581 | Z814 |
| W961 | n/a |
| W965 | n/a |
| W971 | n/a |
| W975 | n/a |
| W981 | n/a |
| W986 | n/a |
| O061 | n/a |
| O071 | n/a |
| O081 | n/a |

| 110 1151 | on proceed | | | 9 | | 11 | 1 |
|----------|------------|------|---------|------|-------------|------|---------|
| Main | Anatomy | Main | Anatomy | Main | Anatomy | Main | Anatomy |
| code | code | code | code | code | code | code | code |
| W430 | | W459 | Z814 | W980 | Z813 | W601 | |
| W430 | | W490 | Z814 | W982 | Z814 | W602 | |
| W430 | | W492 | Z814 | W983 | | W603 | |
| W430 | | W493 | Z814 | W984 | | W608 | |
| W432 | | W498 | Z814 | W985 | | W609 | |
| W432 | | W499 | Z814 | W987 | | W611 | |
| W432 | | W500 | Z814 | W988 | | W612 | |
| W432 | n/o | W502 | Z814 | W989 | | W613 | |
| W433 | 11/a | W503 | Z814 | O060 | | W618 | |
| W433 | | W508 | Z814 | O062 | | W619 | One of |
| W433 | | W509 | Z814 | O063 | | W621 | Z813, |
| W433 | | W510 | Z814 | O068 | | W622 | Z814, |
| W433 | | W512 | Z814 | O069 | | W628 | Z891 |
| W438 | | W513 | Z814 | O070 | | W629 | |
| W438 | | W514 | Z814 | O072 | | W631 | |
| W438 | | W518 | Z814 | O073 | | W632 | |
| W438 | Z685 | W519 | Z814 | O078 | <i>m</i> /o | W638 | |
| W439 | Z691 | W580 | | O079 | 11/a | W639 | |
| W439 | Z814 | W580 | | O080 | | W641 | |
| W439 | Z814 | W580 | | O082 | | W642 | |
| W439 | Z685 | W582 | | O083 | | W648 | |
| W440 | Z691 | W582 | | O084 | | W649 | |
| W442 | Z814 | W582 | | O088 | | | |
| W443 | Z814 | W960 | | O089 | | | |
| W443 | Z685 | W962 | nla | X071 | | | |
| W448 | Z691 | W963 | 11/a | X072 | | | |
| W449 | Z814 | W964 | | W572 | | | |
| W450 | Z814 | W966 | | W573 | | | |
| W452 | Z814 | W968 | | W574 | | | |
| W453 | Z685 | W969 | | W575 | | | |
| W453 | Z691 | W970 | | W579 | | | |
| W454 | Z814 | W972 | | Y037 | | | |
| W454 | Z814 | W973 | | | | | |
| W454 | Z685 | W974 | Z691 | | | | |
| W454 | Z691 | W976 | Z813 | | | | |
| W454 | Z814 | W978 | Z814 | | | | |
| W458 | Z814 | W979 | Z691 | | | | |

Revision procedure codes (OPCS-4)

| Procedure description | Main | Anatomy | Notes |
|--------------------------|------|---------|-----------------------|
| _ | code | code | |
| Subacromial | O291 | | |
| decompression or ACJ | W572 | Z812, | Z814 only before 2009 |
| excision | | Z814 | |
| | W844 | Z812, | |
| | | Z814, | |
| | | Z891 | |
| | T621 | Z814, | |
| | T622 | Z891 | |
| | T626 | | |
| | T628 | | |
| | T629 | | |
| Rotator cuff repair | T791 | | |
| | T793 | | |
| | T794 | | |
| | T795 | | |
| | T641 | Z742 | |
| | T642 | | |
| | T643 | | |
| | T744 | | |
| | T648 | | |
| | T649 | | |
| | T67 | | |
| | T68 | | |
| Relocation of dislocated | W652 | Z813, | |
| prosthesis | W658 | Z814, | |
| | W689 | Z891 | |
| | W662 | | |
| | W668 | | |
| | W669 | | |
| | W672 | | |
| | W674 | | |
| | W678 | | |
| | W679 | | |
| Stabilisation procedure | O27 | | |
| | W77 | | Not W776 |
| | W841 | | |
| | W842 | | |
| | W72 | Z813, | |
| | W73 | Z814, | |
| | W74 | Z891 | |
| | W75 | | |

Reoperation procedure codes (OPCS-4)

| Procedure description | Main | Anatomy | Notes |
|-------------------------|------|---------|----------|
| | code | code | |
| MUA +- capsular release | W911 | Z813, | |
| | W913 | Z814, | |
| | W918 | Z891 | |
| | W919 | | |
| | W781 | | |
| | W784 | | |
| | Y421 | | |
| | Y428 | | |
| | Y429 | | |
| Fracture fixation | W19 | Z691, | Not W191 |
| (excluding prosthesis | W20 | Z692, | |
| revision) | W21 | Z693, | |
| | W22 | Z813, | |
| | W23 | Z814, | |
| | W24 | Z891 | Not W241 |
| | W25 | | |
| | W26 | | |
| | W651 | | |
| | W653 | | |
| | W654 | | |
| | W656 | | |
| | W661 | | |
| | W663 | | |
| | W664 | | |
| | W671 | | |
| | W673 | | |
| | W677 | | |
| | W332 | | |
| | 0172 | | |
| | 0173 | | |
| | O175 | | |
| | 0178 | | |
| | 0179 | | |
| Synovectomy | W691 | Z813, | |
| | W692 | Z814, | |
| | W693 | Z891 | |
| | T711 | | |

Reoperation procedure codes (OPCS-4) - continued

| Indication | Primary | ICD-10 | OPCS-4 code | s in patient |
|-----------------|----------------|----------------|--------------------|--------------|
| | ICD-10 code | codes in | history | I |
| | | patient | · · | |
| | | history | | |
| | | - | Main code | Anatomy |
| | EIGHED | 0.0 | 0.0 | code |
| T | ETTHER C705 | UK | UK | |
| Tumour | C/95 | | | |
| | C400 | | | |
| | M122 | | | |
| | | | | |
| | C82 | | | |
| | C83 | | | |
| | C84 | | | |
| | C85 | | | |
| | C90 | | | |
| | D160 | | | |
| | C/64 S/20 | | | |
| Acute trauma | S420 | | | |
| | S421 | | | |
| | S422 | | | |
| | 5427 | | | |
| | S429 | | | |
| | S430 | | | |
| | S431 S434 | | | |
| | S434 S435 | | | |
| Previous trauma | M125 | \$420 | 027 | |
| | M191 | \$420 \$421 | W77 | Not W776 |
| | T846 | \$421 \$422 | W841 | |
| | M8721 | \$427 \$427 | W842 | |
| | M8722 | \$429 | W72 | 7813 7814 |
| | M8401 | S420 | W72 | 7891 |
| | M8402 | S431 | W74 | 2091 |
| | M8411 | S434 | W75 | - |
| | M8412 | S435 | W652 | - |
| | 10112 | 0100 | W658 | - |
| | | | W689 | - |
| | | | W662 | - |
| | | | W668 | 1 |
| | | | W669 | 1 |
| | | | W672 | 1 |
| | | | W674 | 1 |
| | | | W678 | 1 |
| | | | W679 | 1 |

Primary indication codes

| Indication | Primary | ICD-10 | OPCS-4 codes in patient | | |
|-------------------------|-------------|----------|--------------------------------|-----------------|--|
| | ICD-10 code | codes in | history | | |
| | | patient | · · · | | |
| | | history | | | |
| | | | Main code | Anatomy code | |
| | EITHER | OR | OR | | |
| AVN | M8701 | | | | |
| | M8702 | | | | |
| | M8711 | | | | |
| | M8712 | | | | |
| | M8731 | | | | |
| | M8732 | | | | |
| | M8741 | | | | |
| | M8742 | | | | |
| | M8751 | | | | |
| | M8752 | | | | |
| | M8761 | | | | |
| | M8762 | | | | |
| | M9051 | | | | |
| | M9052 | | | | |
| Inflammatory | M02 | | | | |
| - | M03 | | | | |
| | M05 | | | | |
| | M06 | | | | |
| | M07 | | | | |
| | M08 | | | | |
| | M09 | | | | |
| | M10 | | | | |
| | M11 | | | | |
| | M12 | | | | |
| OA/Cuff Tear arthopathy | M15 | | T791 | | |
| | M19 | | T793 | | |
| | S460 | | T794 | | |
| | M751 | | T795 | | |
| | | | T641 | Z742 | |
| | | | T642 | | |
| | | | T643 | | |
| | | | T744 | | |
| | | | T648 | | |
| | | | T649 | | |
| | | | T67 | | |
| | | | T68 | | |

Primary indication codes - continued

| Condition | ICD-10 | Descriptor |
|---------------------|--------|--|
| | code | |
| | | |
| Pulmonary | | |
| embolism | 126 | Pulmonary embolism |
| | | |
| Myocardial | I21 | Acute myocardial infarction |
| infarction | 122 | Subsequent myocardial infarction |
| | | |
| | J12 | Viral pneumonia, not elsewhere classified |
| Lower respiratory | J13 | Pneumonia due to Streptococcus pneumoniae |
| tract infection | J14 | Pneumonia due to Haemophilis influenzae |
| | J15 | Bacterial pneumonia, not elsewhere classified |
| | | Pneumonia due to other infectious organisms, not |
| | J16 | elsewhere classified |
| | J18 | Pneumonia, organism unspecified |
| | J22 | Unspecified acute lower respiratory infection |
| | J86 | Pyothorax |
| | | Chronic obstructive pulmonary disease with acute lower |
| | J440 | respiratory infection |
| | J851 | Abscess of lung with pneumonia |
| | J690 | Aspiration pneumonia |
| | | |
| Acute kidney injury | N17 | Acute renal failure |
| | | |
| | N10 | Acute tubulo-interstitial nephritis |
| | N300 | Acute cystitis |
| | N308 | Other cystitis |
| Urinary tract | N309 | Cystitis, unspecified |
| infection | N390 | Urinary tract infection, site not specified |
| | | |
| | I60 | Subarachnoid haemorrhage |
| | I61 | Intracerebral haemorrhage |
| | I62 | Other nontraumatic intracranial haemorrhage |
| Cerebrovascular | I63 | Cerebral infarction |
| event | I64 | Stroke, not specified as haemorrhage or infarction |

Serious systemic complications